Arbutus Biopharma
ABUS
ABUS
94 hedge funds and large institutions have $86.5M invested in Arbutus Biopharma in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0.96% more ownership
Funds ownership: 26.25% → 27.21% (+0.96%)
46% less call options, than puts
Call options by funds: $1.89M | Put options by funds: $3.5M
Holders
94
Holding in Top 10
–
Calls
$1.89M
Puts
$3.5M
Top Buyers
| 1 | +$3.46M | |
| 2 | +$2.56M | |
| 3 | +$2.25M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.99M |
| 5 |
Renaissance Technologies
New York
|
+$1.89M |
Top Sellers
| 1 | -$7.1M | |
| 2 | -$1.6M | |
| 3 | -$972K | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$878K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$680K |